Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8266 to 8280 of 8887 results

  1. Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

    Discontinued Reference number: GID-TA10320

  2. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

  3. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued Reference number: GID-TA10329

  4. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued Reference number: GID-TA10337

  5. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued Reference number: GID-TA10338

  6. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

  7. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued Reference number: GID-TA10355

  8. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued Reference number: GID-TA10365

  9. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

  10. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    In development Reference number: GID-TA11092 Expected publication date: TBC

  11. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued Reference number: GID-TA11004

  12. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development Reference number: GID-TAG406 Expected publication date: TBC

  13. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

  14. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

  15. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416